Catalyst
Slingshot members are tracking this event:
Clovis (CLVS) Presents Data on Two Phase 2 Studies of Rucaparib in Treatment-Resistant Ovarian Cancer at the European Society for Medical Oncology 2016 Congress
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CLVS |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 07, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Ariel2, Study 10, European Society For Medical Oncology, Rucaparib, Treatment-resistant Ovarian Cancer